Joseph M Zabramski1, M Yashar S Kalani2, Aristotelis S Filippidis2, Robert F Spetzler2. 1. Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Electronic address: Neuropub@dignityhealth.org. 2. Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
Abstract
BACKGROUND: Cerebral cavernous malformations are more common than generally thought, affecting approximately 1 in every 250 adults. Most of these lesions are asymptomatic or have a relatively benign course, but a small minority behave aggressively and present with recurrent episodes of symptomatic hemorrhage. A safe and effective medical treatment option for the management of this latter group would be useful. Propranolol has recently been shown to be effective in the treatment of infantile hemangioma, a close pathologic counterpart of cavernous malformations. These results suggest a potential role for propranolol treatment in the management of patients with symptomatic cavernous malformations. METHODS: Low-dose propranolol (20 mg, three times daily) was used to treat 2 adult female patients in their mid- to late fifties, both of whom had symptomatic cavernous malformations and a history of repeated hemorrhage. Serial magnetic resonance imaging studies after the initiation of propranolol demonstrated regression of the lesions and no evidence of recurrent hemorrhage. CONCLUSIONS: Propranolol may offer a safe and effective treatment for patients who have cavernous malformations with symptomatic hemorrhage. Additional studies are needed to confirm these findings.
BACKGROUND: Cerebral cavernous malformations are more common than generally thought, affecting approximately 1 in every 250 adults. Most of these lesions are asymptomatic or have a relatively benign course, but a small minority behave aggressively and present with recurrent episodes of symptomatic hemorrhage. A safe and effective medical treatment option for the management of this latter group would be useful. Propranolol has recently been shown to be effective in the treatment of infantile hemangioma, a close pathologic counterpart of cavernous malformations. These results suggest a potential role for propranolol treatment in the management of patients with symptomatic cavernous malformations. METHODS: Low-dose propranolol (20 mg, three times daily) was used to treat 2 adult female patients in their mid- to late fifties, both of whom had symptomatic cavernous malformations and a history of repeated hemorrhage. Serial magnetic resonance imaging studies after the initiation of propranolol demonstrated regression of the lesions and no evidence of recurrent hemorrhage. CONCLUSIONS:Propranolol may offer a safe and effective treatment for patients who have cavernous malformations with symptomatic hemorrhage. Additional studies are needed to confirm these findings.
Authors: Sean P Polster; Ying Cao; Timothy Carroll; Kelly Flemming; Romuald Girard; Daniel Hanley; Nicholas Hobson; Helen Kim; James Koenig; Janne Koskimäki; Karen Lane; Jennifer J Majersik; Nichol McBee; Leslie Morrison; Robert Shenkar; Agnieszka Stadnik; Richard E Thompson; Joseph Zabramski; Hussein A Zeineddine; Issam A Awad Journal: Neurosurgery Date: 2019-04-01 Impact factor: 4.654
Authors: Virginia Albiñana; Rosa María Jiménez Escribano; Isabel Soler; Luis Rodríguez Padial; Lucia Recio-Poveda; Karina Villar Gómez de Las Heras; Luisa María Botella Journal: Orphanet J Rare Dis Date: 2017-06-29 Impact factor: 4.123
Authors: Matthew R Detter; Robert Shenkar; Christian R Benavides; Catherine A Neilson; Thomas Moore; Rhonda Lightle; Nicholas Hobson; Le Shen; Ying Cao; Romuald Girard; Dongdong Zhang; Erin Griffin; Carol J Gallione; Issam A Awad; Douglas A Marchuk Journal: Angiogenesis Date: 2020-07-24 Impact factor: 9.596
Authors: Silvia Lanfranconi; Elisa Scola; Giulio Andrea Bertani; Barbara Zarino; Roberto Pallini; Giorgio d'Alessandris; Emanuela Mazzon; Silvia Marino; Maria Rita Carriero; Emma Scelzo; Giuseppe Faragò; Marco Castori; Carmela Fusco; Antonio Petracca; Leonardo d'Agruma; Laura Tassi; Piergiorgio d'Orio; Maria Grazia Lampugnani; Enrico Bjorn Nicolis; Antonella Vasamì; Deborah Novelli; Valter Torri; Jennifer Marie Theresia Anna Meessen; Rustam Al-Shahi Salman; Elisabetta Dejana; Roberto Latini Journal: Trials Date: 2020-05-12 Impact factor: 2.279